P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Po-Wei ChenWen-Han FengMing-Yun HoChun-Hung SuSheng-Wei HuangChung-Wei ChengHung-I YehChing-Pei ChenWei-Chun HuangChing-Chang FangHui-Wen Lin Sheng-Hsiang LinI-Chang HsiehYi-Heng LiPublished in: Journal of clinical medicine (2020)
Among patients with ACS undergoing PCI who cannot complete course of dual antiplatelet therapy, a significantly lower risk of cardiovascular events was associated with ticagrelor monotherapy than with clopidogrel monotherapy. The major bleeding risk was similar in both the groups.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- cardiovascular events
- coronary artery disease
- st segment elevation myocardial infarction
- combination therapy
- st elevation myocardial infarction
- acute myocardial infarction
- open label
- coronary artery bypass grafting
- atrial fibrillation
- cardiovascular disease
- coronary artery bypass
- heart failure